DS
NXTC icon

David Shaw’s NextCure NXTC Stock Holding History

David Shaw’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,155
Closed -$19.5K – 4735
2022
Q4 		$19.5K Buy
+1,155
New +$26.6K ﹤0.01% 4529
2021
Q4 		– Sell
-1,065
Closed -$86K – 5616
2021
Q3 		$86K Sell
1,065
-2,018
-65% -$177K ﹤0.01% 4742
2021
Q2 		$297K Sell
3,083
-613
-17% -$62.7K ﹤0.01% 4282
2021
Q1 		$444K Buy
3,696
+250
+7% +$36.2K ﹤0.01% 3558
2020
Q4 		$451K Buy
+3,446
New +$445K ﹤0.01% 3435
2020
Q3 		– Sell
-6,514
Closed -$1.68M – 4055
2020
Q2 		$1.68M Buy
+6,514
New +$2.48M ﹤0.01% 2547
2020
Q1 		– Sell
-2,022
Closed -$1.37M – 4147
2019
Q4 		$1.37M Buy
+2,022
New +$1.01M ﹤0.01% 2766

Other funds holding NXTC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

David Shaw's NXTC Position: Q1 2023 in Review

David Shaw sold out of NextCure (NXTC) in Q1 2023, closing a stake of 1,155 shares — an estimated $19.5K sold.

David Shaw first reported a position in NXTC in Q4 2019 and held it in 7 quarters. The position peaked at $1.68M in Q2 2020. 43 funds tracked by Wall St. Rank hold NXTC as of Q1 2023.

  • David Shaw reported no remaining NextCure position as of Q1 2023 after selling out during the quarter.
  • David Shaw sold 1,155 NextCure shares in Q1 2023, an estimated $19.5K.
  • David Shaw first reported a position in NextCure in Q4 2019 and held it in 7 quarters.
  • David Shaw's NextCure position peaked at $1.68M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held NextCure as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.